Skip to content

Aptamer Blog

Aptamers for Covid-19

Neo Ventures Announcement

    NeoVentures has successfully developed aptamers for both the spike protein and the nucleoprotein of SARS-CoV-2 (COVID-19). Spike protein aptamers were developed against a recombinant S1 protein from the Wuhan strain expressed in HEK293 cells in order to maintain appropriate glycosylation, counter selection was performed against… Read More »Neo Ventures Announcement

    Aptamers in therapeutics ? (Why not)

      Why are there not more aptamer based therapeutics?¬† This blog by Drew Smith in 2019 nails a lot of the reasons, and in particular the issues related to the rapid clearance of aptamers from the body. He effectively points out that the aptamer that… Read More »Aptamers in therapeutics ? (Why not)

      Optimized Aptamers II

        In a previous blog I stressed the need to further improve aptamer performance after SELEX identification in order to develop aptamers that are effective enough to be commercialized. I promised that I would describe how we do this at NeoVentures in more detail in a… Read More »Optimized Aptamers II

        Optimized Aptamers

          For aptamers to be able to compete with antibodies in health care applications they need to perform as well as antibodies. At NeoVentures we have considered how antibodies evolve in response to an antigen and we have applied a similar approach to the optimization of… Read More »Optimized Aptamers